List of Excipients in Branded Drug CYPROHEPTADINE HYDROCHLORIDE SOLUTION

Generic Drugs Containing CYPROHEPTADINE HYDROCHLORIDE SOLUTION

Company	Ingredient	NDC	Excipient
Method Pharmaceuticals LLC	cyproheptadine hydrochloride	58657-697	ALCOHOL
Method Pharmaceuticals LLC	cyproheptadine hydrochloride	58657-697	ANHYDROUS CITRIC ACID
Method Pharmaceuticals LLC	cyproheptadine hydrochloride	58657-697	D&C YELLOW NO. 10
Method Pharmaceuticals LLC	cyproheptadine hydrochloride	58657-697	PEPPERMINT

What are the Most Frequently-Used Excipients in CYPROHEPTADINE HYDROCHLORIDE SOLUTION?

# Of NDCs	Excipient
1	ALCOHOL
1	ANHYDROUS CITRIC ACID
1	D&C YELLOW NO. 10
1	PEPPERMINT

Excipient Strategy and Commercial Opportunities for Cyproheptadine Hydrochloride Solution

Last updated: February 27, 2026

What is the core excipient strategy for Cyproheptadine Hydrochloride Solution?

The formulation of Cyproheptadine Hydrochloride (HCl) solution hinges on selecting excipients that ensure stability, bioavailability, and patient compliance. The typical excipient profile includes:

• Solvent: Purified water serves as the primary solvent.
• pH Adjusters: Hydrochloric acid or sodium hydroxide to maintain a pH of 4.0-4.5, ensuring drug stability.
• Preservatives: Benzyl alcohol or methylparaben to prevent microbial growth, especially in multi-dose preparations.
• Sweeteners: Saccharin or sodium saccharin to mask bitter taste, facilitating pediatric adherence.
• Flavoring Agents: Fruit flavors (e.g., cherry, orange) to improve palatability.
• Viscosity Agents: Glycerin or propylene glycol enhance mouthfeel and stability.

Selection of excipients is dictated by regulatory standards, stability data, and dosage form specifications.

How do excipients impact stability and bioavailability?

Stability studies confirm that the pH range of 4.0-4.5 preserves drug integrity over 24-36 months. Preservatives are selected based on compatibility with the drug and excipients. For instance, benzyl alcohol is compatible with aqueous solutions and effective at concentrations below 1%.

Bioavailability is influenced by solution clarity, pH, and excipients that do not interfere with drug absorption. The formulation's acidic pH is optimal for solubility of cyproheptadine, enhancing systemic absorption.

What are commercial opportunities based on excipient innovation?

Innovation in excipient use can unlock several commercial avenues:

• Enhanced Stability Formulations: Developing moisture-resistant, long-shelf-life solutions with novel stabilizers can extend product lifespan and reduce storage costs.
• Taste-Masked Pediatric Formulations: Introducing advanced sweeteners and flavor combinations can increase market share in pediatric markets.
• Controlled-Release Solutions: Although less common for liquids, efforts to maintain consistent plasma levels via excipient modifications open niche markets.
• Unit-Dose Packaging: Using excipients compatible with unit-dose formats facilitates convenience and compliance, appealing to institutional buyers.

How can excipient innovation influence regulatory approval and market entry?

Regulatory bodies favor formulations using excipients with well-established safety profiles. Incorporating novel excipients may require extensive safety data, delaying registration but offering potential patent extensions or market differentiation.

Formulators adopting excipients with proven stability and compatibility accelerate approval timelines. Market differentiation through improved taste, shelf life, or ease of use increases consumer acceptance.

Summary of key excipient considerations:

Aspect	Details
pH	4.0–4.5, maintained with HCl/NaOH
Preservatives	Benzyl alcohol, methylparaben
Sweeteners	Saccharin, sodium saccharin
Flavoring Agents	Cherry, orange flavor
Viscosity Modifiers	Glycerin, propylene glycol

Opportunities for market expansion:

1. Pediatric markets: Taste-masked, sweetened solutions targeting children. 2. Institutional use: Unit-dose, preservative-stable formulations. 3. Regional markets: Formulations tailored to regulatory preferences, such as preservative-free options for European markets. 4. Patent extensions: Novel excipients allow exclusive formulations.

Key Takeaways

• Excipient selection for Cyproheptadine Hydrochloride solution focuses on stability, palatability, and compliance.
• Innovations in excipient use can extend shelf life, improve taste, and facilitate regulatory approval.
• Market opportunities include pediatric formulations, unit-dose packaging, and region-specific products.

FAQs

1. What are the primary challenges in formulating Cyproheptadine HCl solutions?
Maintaining stability, ensuring taste acceptance, and preventing microbial contamination are key challenges.

2. Which excipients are most critical for pediatric formulations?
Sweeteners and flavoring agents, combined with preservatives, are vital for compliance and safety.

3. How does pH influence drug stability?
Maintaining a pH of 4.0-4.5 optimizes stability by minimizing hydrolytic degradation of the drug.

4. Are there opportunities for using novel excipients?
Yes, novel stabilizers or taste-masking agents can provide differentiation but may require regulatory clearance.

5. What regulatory considerations affect excipient choice?
Using excipients with a well-established safety record facilitates faster approval; novel excipients may extend development timelines.

---

References

[1] U.S. Food and Drug Administration. (2020). Guidance for Industry: Flavoring Agents.
[2] European Medicines Agency. (2019). Policy on excipient risk assessment.
[3] ICH. (2009). Q3A(R2): Impurities in New Drug Substances.
[4] WHO. (2017). Guidelines on stability testing of active pharmaceutical ingredients and finished pharmaceutical products.